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The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous
morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was
performed in 25 cancer patients receiving stable opioid doses. For each episode, when it occurred and 15 and 30min after the
treatment, pain intensity and opioid-related symptoms were recorded. Fifty-three couples of breakthrough events, each treated with
IV-MO and OTFC, were recorded. In episodes treated with IV-MO, pain intensity decreased from a mean of 6.9 to 3.3 and to 1.7 at
T1 and T2, respectively. In episodes treated with OTFC, pain intensity decreased from a mean of 6.9 to 4.1 and to 2.4 at T1 and T2,
respectively. Statistical differences between the two treatments were found at T1 (P¼0.013), but not at T2 (P¼0.059). Adverse
effects were comparable and were not significantly related with the IV-MO and OTFC doses. Intravenous morphine and OTFC in
doses proportional to the scheduled daily dose of opioids were both safe and effective, IV-MO having a shorter onset than OTFC.
Future comparative studies with appropriate design should compare titration methods and proportional methods of OTFC dosing.
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Patients with chronic cancer pain often report wide fluctuations in
pain intensity. In the cancer population, breakthrough pain (or
episodic pain) is a transitory flare of pain superimposed on an
otherwise stable pain pattern in patients treated with opioids
(Portenoy et al, 1999a). The availability of supplemental doses of
opioids (rescue medication) in addition to the continuous
analgesic medication is the main treatment suggested to manage
these pain flares. Current dosing recommendations for break-
through pain generally suggest that the effective dose of break-
through pain medication must be a percentage of a patient’s total
daily opioid dose (Hanks et al, 2001). These recommendations,
which are based entirely on anecdotal experience, favour the
selection of a short-acting opioid at a dose proportionate to the
total daily dose. However, an oral dose form can take a longer time
to relieve pain. As pain relief is usually required urgently, routes of
administration designed to deliver drugs rapidly are often chosen.
A short onset of effect is commonly obtainable only with
parenteral or transmucosal administration of opioid analgesics.
Intravenous morphine (IV-MO) has been found to be highly
effective and safe, as only a low intensity of opioid-induced adverse
effects was observed, even when administering large doses
(Mercadante et al, 2004). While the intravenous route for
morphine administration is feasible in acute units, in some other
centres is not favourite, and at home injections are not easily
manageable.
On the other hand, studies of oral transmucosal fentanyl citrate
(OTFC) have shown that this approach produces a faster onset of
relief and a greater degree of pain relief than the oral morphine, at
15, 30, and 60min (Christie et al, 1998; Farrar et al, 1998; Portenoy
et al, 1999b; Coluzzi et al, 2001). A lack of relationship between the
effective OTFC dose and the fixed schedule opioid regimen,
regardless of the opioid used, was observed suggesting the need to
titrate the dose of OTFC. This observation contradicted the
anecdotal assumption that the effective dose as needed is a
percentage of the opioid daily dose. The reasons for the above
finding have not been clearly explained. This makes the practical
use of OTFC in the raw clinical setting, or at home, difficult.
Moreover, using different pieces of OTFC for treating each episode
may be time consuming exceeding the spontaneous duration for
breakthrough pain, which can spontaneously subside, as evidenced
by placebo-treated patients.
From the practical point of view, in our daily activity, most
patients have been reluctant to try the dose, either on in-patient or
outpatient basis, and avoid using the OTFC, preferring, at the end,
traditional oral dosing of morphine. The aim of this randomised,
crossover, controlled study was to verify the safety and effective-
ness of a fixed dose of OTFC, proportional to the daily dose,
compared to the standard treatment available in the unit, which
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sis IV-MO, used in a similar way for the management of
breakthrough pain.
PATIENTS AND METHODS
This is a randomised, crossover, controlled study comparing the
effectiveness of a fixed dose of OTFC and IV-MO, for the
management of breakthrough pain. A consecutive sample of 105
cancer patients, who were admitted to a Pain Relief and Palliative
Care unit for a period of 1 year, receiving a stable opioid dose of
oral morphine or transdermal fentanyl for their cancer-related
pain reporting an acceptable pain relief, was screened for the
study. Ethical committee approval was obtained.
Study population
Adult patients with cancer-related pain were eligible if they were
receiving opioids regularly at doses of more than 60mg of oral
morphine equivalents, had an acceptable pain relief, and presented
no more than two pain flares per day. Patients were excluded from
the study if they had important metabolic alterations, cognitive
failure, lack of cooperation, or extreme ages (under 18 and over 80
years). Patients with predominant incident pain or with short-lived
episodes of neuropathic pain resolving spontaneously in few
minutes were also excluded. Finally, patients receiving oral
morphine equivalents in a dose range of 270–330mg (see below),
and patients who presented more than two episodes or just one
episode during the daily hours (from 0700 to 1900), or pain flares
repeating after with short intervals (less than 6h) were also
excluded (see the protocol described below).
Forty patients met the inclusion criteria and gave their informed
consent. According to the department policy, an intravenous line
was established for emergency treatment of symptoms. Increases
of pain intensity were considered only if patients felt that there was
a clear difference with basal pain and required a medication as
needed. Patients were encouraged to call when their pain got
severe.
Procedures
Patients were planned to receive IV-MO and OTFC for each couple
of breakthrough pain events. The order of administration was
computer-generated to produce equivalent sequence orders, 50–
50%, and the wash out period between the pain flares was at least
6h. Patients who repeated the sequence on another day received
the opposite sequence. Only patients presenting a couple of
episodes occurring between 0700 and 1900 were taken into
consideration. Thus, patients received both treatments, serving
as their own control. Patients who presented more than two
episodes or just one episode during the daily hours (from 0700 to
1900) were excluded, so that only days in which two episodes
occurred within this interval of 12h were considered, to assure the
presence of physicians in the unit, and minimise the occurrence of
possible complications.
The rationale in choosing the doses to be administered was
based on a previous experience with IV-MO in doses of 4mg in
patients receiving an equivalent dose of oral morphine of 60mg
(Mercadante et al, 2004), and on the suggestion from previous
studies of OTFC that 200mg OTFC should be administered in
patients receiving at least 60mgday
 1 of oral morphine or
25mgh
 1 (0.6mgday
 1) of transdermal fentanyl (Christie et al,
1998; Farrar et al, 1998; Portenoy et al, 1999b; Coluzzi et al, 2001).
This does not mean that the dose of the two drugs is equianalgesic,
despite some information drawn from previous local experience
and studies performed in other settings (Lichtor et al, 1999).
The IV-MO dose was administered for about 5min at 1/5 of
the oral daily dose, converted using an equianalgesic ratio of 1/3
(IV/oral) (Mercadante et al, 2004). For example, a daily morphine
oral dose of 60mg corresponds to an intravenous dose of 20mg (1/
3 ratio), and then is converted to 4mg (20%), to be used as the
dose for episodic pain. Written orders were given and IV-MO was
administered by nurses, already trained in using such an approach,
as a standard practice of the unit. Oral transmucosal fentanyl
citrate was administered, after a previous explanation of the use,
by patients themselves, also assisted by nurse, in doses propor-
tional to the basal daily opioid dose, as described for IV-MO.
Doses were rounded off to the closest value for patients receiving
intermediate dosages. Only one stick of OTFC was used. Thus,
patients receiving oral morphine equivalents in the dose range of
270–330mg were excluded, owing to unavailability of the
calculated dose of OTFC (1000mg).
For each episode, when it occurred (T0), 15min after (T1), and
30min after (T2) the study of drug administration, patients were
asked about the following parameters, which were recorded: pain
intensity, using a numerical scale from 0 to 10, and opioid-related
symptoms, using a scale from 0 to 3 (absent, slight, moderate,
severe). These scales have been reported in several previous
papers on same subject (Mercadante et al, 2004, 2005, 2006), are
familiar to the staff, and represent the standard in the unit.
Data were collected by nurses trained in symptom measurement
as a part of their daily activity. They were also previously trained
for data collection of breakthrough pain events. This tertiary
unit offers a high level of nurse training and monitoring
(Mercadante et al, 2003; Fine, 2005). In particular, for each
episode, nurses were instructed to routinely collect changes in pain
intensity (numerical scale 0–10) and emerging problems: when
they are called for pain increases considered to be severe in
intensity by patients (T0), 15min after IV-MO injection (T1) and
30 after (T2).
Daily doses of oral morphine equivalents and basal pain
intensity were also recorded. A decrease in pain intensity of at
least 433% at T1, not requiring further treatment for the next 2h,
was considered as an effective treatment of each episode. Patients
were offered the common prescription used in the unit, that is IV-
MO, but at half dose, if they were not satisfied with the treatments
within T1.
Data analysis
A power analysis indicated that a sample size of 25 episodes per
group would allow to detect a 20% difference (Po0.05,
power¼0.8). This computation assumes that the mean difference
is 0.20 with a 95% confidence interval (CI) of 0.07–0.33 and the
common within-group standard deviation of 0.28.
Frequency analysis was performed with w
2 test. The univariate
and multivariate repeated measures analysis (analysis of variance
(ANOVA)) was used to compare the scores or the means of non-
parametric and parametric variables, respectively, at different time
intervals. The one-way ANOVA and Mann–Whitney U statistic
test were used to compare the different parametric or non-
parametric variables. All P-values were two-sided and P-values less
than 0.05 were considered statistically significant.
RESULTS
Patients’ characteristics are listed in Tables 1 and 2. All patients
had their basal pain under control (mean 2.9, 95% CI 2.3–3.6).
Fifteen patients were excluded from the study: four patients were
unable to use OTFC, two patients had more than two episodes
between 0700 and 1900, nine patients had just one episode to treat
(Figure 1).
Twenty-five patients completed 53 couples of breakthrough
events (a mean of 2.12 couple of episodes for each patient,
recorded on different days), each randomly treated with IV-MO
Intravenous morphine and OTFC doses
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sand OTFC, during admission. A total of 25 couples were IV-MO/
OTFC sequences, and 28 couples were OTFC/IV-MO sequences.
In episodes treated with IV-MO, pain intensity decreased from
6.9 (95% CI 6.6–7.2) to 3.3 (95% CI 2.7–3.8) and 1.7 (95% CI 1.2–
2.3) at T1 and T2, respectively. This reduction was more than 33%
in 39 (74%) and in 46 episodes (87%) at T1 and T2, respectively,
and more than 50% in 29 (55%) and in 40 episodes (75%), at T1
and T2, respectively.
In episodes treated with OTFC, pain intensity decreased from
6.9 (95% CI 6.6–7.2) to 4.1 (95% CI 3.6–4.7) and 2.4 (95% CI 1.8–
2.9) at T1 and T2, respectively. This reduction was more than 33%
in 30 (57%) and 45 episodes (85%) at T1 and T2, respectively, and
more than 50% in 20 (38%) and in 40 episodes (75%) at T1 and T2,
respectively.
A statistical difference between the two treatments was found at
T1 (P¼0.013, univariate repeated measures analysis ANOVA),
whereas at T2 the difference did not attain a statistical significance
(P¼0.059, univariate repeated measures analysis ANOVA). Three
patients and one patient who had received OTFC and IV-MO,
respectively, required an additional (half) dose of IV-MO, as a
further rescue dose. When excluding these patients with the
intention for protocol analysis, a statistical difference was similarly
found at T1 (P¼0.049), but not at T2 (P¼0.124).
At T1, a decrease of 41.4 and 51.7% in pain intensity was
observed after OTFC and IV-MO, respectively (P¼0.026). At T2, a
decrease of 65.9 and 73.8% in pain intensity was recorded after
OTFC and IV-MO, respectively (P¼0.136). No differences between
the two groups were observed in the number of episodes with a
reduction of more than 33 and 50% at T1 (P¼0.66 and 0.39) and
T2 (P¼0.23 and 0.20), respectively.
The outcome was not related to the basal regimen, and as a
consequence to IV-MO and OTFC doses. Statistical tests with exact
critical values were performed to evaluate differential carryover
effect and period effect between treatments. There were no
Table 1 Characteristics of patients
No. of patients 25
Age 59 (95% CI 55–63)
Gender (M/F) 12/13
Pain characteristics
Somatic 9
Somatic–visceral 3
Somatic–neuropathic 3
Visceral 4
Visceral–neuropathic 2
Neuropathic 4
Basal morphine dose 120mg (95% CI 96–144)
OTFC/IV-MO
200/4 Six patients available for nine drug sequences (in different days)¼1.5 sequence for patient
400/8 Three patients available for five drug sequences (in different days)¼1.6 sequence for patient
600/12 Five patients available for 14 drug sequences (in different days)¼2.8 sequences for patient
800/16 One patient available for six drug sequences (in different days)¼6 sequences for patient
1200/24 Eight patients available for 13 drug sequences (in different days)¼1.62 sequences per patient
1600/32 Two patients available for six drug sequences (in different days)¼3 sequences per patient
CI¼confidence interval; IV-MO¼intravenous-morphine; OTFC¼oral transmucosal fentanyl citrate. Age (mean), gender, pain mechanisms, basal oral morphine equivalent
doses (mean and 95% CI). Doses of OTFC (mg) and IV-MO (mg), number of patients and number of sequences for each patient for any dose level of OTFC and IV-MO.
Table 2 Changes of pain intensity 15 and 30min after treatment in all patients, and in patients using different ranges of basal opioid doses (o120, 120–
270, and 4330mg of oral morphine equivalents, respectively)
T0 T1 T2
OTFC 6.9 (6.6–7.2) 4.1 (3.5–4.7) 2.4 (1.8–2.9)
IV-MO 6.9 (6.6–7.2) 3.3 (2.7–3.8)* 1.7 (1.2–2.3)**
p120mg of oral morphine equivalents
9 patients/14 events
OTFC 6.1 (5.4–6.7) 3.7 (2.5–4.8) 2.4 (1.0–3.8)
IV-MO 6.3 (5.8–6.8) 3.2 (2.2–4.3) 1.7 (0.5–3.0)
4120–270mg of oral morphine equivalents
14 patients/33 events
OTFC 7.2 (6.8–7.5) 4.5 (3.7–5.3) 2.6 (1.8–3.3)
IV-MO 7.1 (6.6–7.5) 3.5 (2.8–4.2) 1.9 (1.2–2.7)
4330mg of oral morphine equivalents
2 patients/6 events
OTFC 7.1 (6.6–7.6) 3.7 (2.3–5.1) 1.9 (0.6–3.2)
IV-MO 7.1 (6.3–7.8) 2.7 (1.4–4.1) 1.2 (0–2.6)
IV-MO¼intravenous-morphine; OTFC¼oral transmucosal fentanyl citrate. Data are expressed as mean (95% CI). *P¼0.013 and **P¼0.059 (univariate repeated measures
analysis ANOVA, F¼6.694 and 3.732, respectively).
Intravenous morphine and OTFC doses
S Mercadante et al
1830
British Journal of Cancer (2007) 96(12), 1828–1833 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sstatistically significant period or carryover effects (P¼0.82 and
0.19, respectively).
No differences in age, gender, pain mechanism, time of events,
or kind of opioid used as basal regimen were found.
Adverse effects
Acute adverse effects occurring after IV-MO and OTFC were
comparable and corresponded to those commonly observed with
opioid therapy. In most patients, the level of adverse effects after
the study medication was undistinguishable from that owing to
basal opioid analgesia. A minority of episodes were followed by
adverse effects with a certain intensity (2/3 on the scale used).
Moderate adverse effects in episodes treated with OTFC were:
nausea (four episodes), drowsiness (seven episodes), and confu-
sion (one episode). Moderate adverse effects in episodes treated
with IV-MO were: nausea (two episodes), drowsiness (10
episodes), confusion (three episodes) (see Table 3). No severe
adverse effect was recorded. The occurrence of such adverse effects
was not related with the basal dose and, as a consequence, with the
IV-MO or OTFC doses given for breakthrough pain.
DISCUSSION
Despite the growing interest on breakthrough or episodic pain in
the last 10 years, few prospective comparison studies have been
performed. Oral transmucosal fentanyl citrate was compared with
the standard treatment used in the unit, which is an intensive acute
pain relief and palliative care unit, where strict monitoring is
essential and an intravenous line is commonly inserted to achieve
rapidly pain and symptom control. We have also chosen IV-MO as
a control, as this modality could better fit the onset of OTFC for
comparison, although the use of IV-MO is often restricted to
selected palliative care units. While subcutaneous route is more
frequently used in the setting of hospice care, probably, it would
result in an expected delay in the onset of the effect in comparison
with OTFC.
In this comparative trial, although both treatments were
effective, IV-MO had a shorter onset of analgesia in comparison
with OTFC, while producing similar adverse effect profile,
demonstrating safety and effectiveness. A more important
information could be gathered by this study. Oral transmucosal
fentanyl citrate, given in doses proportional to the basal opioid
regimen, was quite effective and, above all, safe, avoiding to titrate
the dose, which is unsuitable for some patients, reducing their
compliance with the treatment. In patients receiving 180mg of oral
morphine equivalents or more, 39 episodes (73.5%) were treated
with doses of 600mg of OTFC or more in the first instance,
producing acceptable adverse effects, which occurred equally,
independently of the dose. This observation contrasts with almost
all studies of OTFC (Christie et al, 1998; Farrar et al, 1998;
Portenoy et al, 1999b; Coluzzi et al, 2001) , where the principal
Excluded (n=15): 
- Refused use of OTFC (n=4)
- More than two episodes between
0700 and 1900 hour in 1 day (n=2)
- Just one episode between 0700 and 1900 hour 
in 1 day (n=9) 
Meeting the inclusion criteria
n=40
25 Patients
Received allocated intervention (n=25)
Episodes treated with OTFC (n=53)
Received allocated intervention (n=25)
Episodes treated with IV-MO (n=53)
Analysed episodes
ITT n=53
IPP n=49
Analysed episodes
ITT n=53
IPP n=49
Assessed for eligibility 
n=105
Figure 1 CONSORT flowchart.
Table 3 Adverse effects with an intensity of 2/3 on the scale used
(moderate intensity) in episodes treated with OTFC and IV-MO
OTFC IV-MO
Nausea 4 (7.5%) 2 (3.7%)
Drowsiness 7 (13.2%) 10 (18.8%)
Confusion 1 (1.8%) 3 (5.6%)
IV-MO¼intravenous-morphine; OTFC¼oral transmucosal fentanyl citrate.
Intravenous morphine and OTFC doses
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sfinding was a lack of correlation of the OTFC dose with the basal
opioid regimen, although some data could be interpreted in
another way. For example, many patients on higher doses of
original medication generally required larger doses of OTFC and in
successful patients the regular rescue dose was a moderate
predictor of the effective OTFC dose. In one of the controlled
studies of OTFC, a relationship between the OTFC dose and the
fixed scheduled opioid had been already found, and regular rescue
dose was a moderate predictor of the effective OTFC dose.
However, only 19% of the variability of the final dose of OTFC was
explained by basal doses of opioids, according to the low-R-square
vale of the model used (Christie et al, 1998). Recent observations
from data pooled from trials of OTFC showed a statistically
significant relationship between the breakthrough dose and the
around-the-clock dose, despite an enormous interindividual
variability in patients’ dose requirements for breakthrough pain
(Hagen et al, 2007).
The aim of the present study was not to compare effective
titrated doses with doses proportional to the scheduled daily doses,
but two fast methods for treating breakthrough pain were
compared, using a similar approach that is providing opioids at
a dose proportional to the basal regimen.
Some issues gathered by these previous studies should be
pointed out. As 66% of the episodes treated with placebo did not
require an additional dose of medication, the episodes recorded
were possibly short-lived or not too much severe, and possibly
spontaneously resolved. This can also explain why minimal doses
of oral morphine equivalents (about 20mg) were effective in
patients taking a mean basal dose of 100mg per hour of fentanyl
(about 240mg daily of oral morphine doses equivalents). Eligible
patients were defined as having their basal pain no more than
moderate, and presenting no more than four episodes per day. On
the other hand, some patients could not be universally considered
(mean intensity of 4.7–4.8 of basal pain, with some patients at
the highest extremes) as having well-controlled pain, especially if
matched with a pain intensity of breakthrough events of 6.8 on
average (with some patients at the lowest extremes). No distinction
was made between incident pain, dependent on activity, and other
mechanisms, which can have a different temporal pattern. Finally,
almost no adverse effects were reported with usual breakthrough
medication in comparison with OTFC, which doses were titrated in
patients apparently responsive to their usual medication, suggest-
ing that probably most patients were undertreated either with
basal or ‘as needed’ medication.
Of interest, in previous studies of OTFC, up to four episodes per
day were treated, suggesting that the treatment was sometime
repeated more frequently than every 6h. Six hours should be a
sufficient interval to avoid overlapping of effects between OTFC
and IV-MO administration and vice versa. On the other hand, the
increase in pain intensity, typical of the breakthrough event, which
triggers drug administration, gives evidence that the effect of the
previous medication is evanished.
In this study, criteria for selecting breakthrough events were
strict. Adequate pain levels (about 3/10 intensity) and severe pain
intensity of the episodes (about 7/10 intensity) were chosen to
make a clear distinction between basal pain intensity and pain flare
intensity. We also selected patients having no more than two
episodes per day, to avoid possible inclusion of patients with
disputable pain control. Specifically, for inclusion, we have chosen
only days when both randomised treatments were used, facilitating
also patients’ compliance for comparison, but at a distance of at
least 6h, to avoid overlapping effects. Given that the study was not
blinded, a learning effect in using OTFC cannot be excluded in
subsequent administrations, but this was inevitable. However, no
particular differences between subjects who received one or more
OTFC treatments were found. When evaluating differential carry-
over effect and period effect between treatments, there were no
statistically significant period or carryover effects. Of interest,
previous studies did not take into consideration an acceptable time
interval between events (Christie et al, 1998; Farrar et al, 1998;
Portenoy et al, 1999b; Coluzzi et al, 2001), included in the present
protocol, and comparison could have paradoxically been inferred
by titration to find an adequate dose and previous selection of
responsive patients to both previous opioids and OTFC (exclusion
of patient owing to adverse effects during open-label titration).
While diminishing the recruitment power, this method was
more selective. Moreover a fixed time for response evaluation was
taken into consideration, as this is an acceptable burden and
timing for patients. Finally, patients who presented clear
characteristics of incident pain due to movement were excluded.
The analgesic treatment of this kind of pain is more difficult to
assess, owing to the predictability of the event and variability in
patients’ behaviour, which can confound the outcome.
To evaluate the effectiveness of a treatment of a 50% cutoff point
for the percentage of maximum pain relief is considered as a
consistent clinical end point of pain half relieved, easily under-
stood by professionals and patients. However, the minimal end
point to efficacy has been found to be a decrease in pain intensity
of at least 433%, 15min after the study medications. This level of
change in pain intensity has been best associated with clinically
important differences by patients (Farrar et al, 2001). As expected,
OTFC has been found to be more effective and rapid than oral
morphine for treating breakthrough pain, producing a 433%
change in about 42% of patients within 15min after administration
(about 32%) (Coluzzi et al, 2001). In an open-label study, this level
was achieved in about 15min in more than 90% of events treated
by IV-MO, despite selection criteria were more strict and included
episodes with a high intensity (more of 7/10 on a numerical scale)
(Mercadante et al, 2004). This finding was confirmed in the
present study, as IV-MO provided clinical differences in about 75%
of treated episodes 15min after injection. Of interest, OTFC, used
in doses proportional to the basal regimen, was effective in about
57% of treated episodes, a percentage higher than that reported in
previous studies (Christie et al, 1998; Farrar et al, 1998; Portenoy
et al, 1999b; Coluzzi et al, 2001).
To test the efficacy of IV-MO and OTFC, two similar episodes
occurring in the same day were selected to make the comparison
easy. In postoperative studies, it has been calculated that OTFC:IV-
MO ratio is 1:10–20 (Lichtor et al, 1999; Lu and Bailey, 2003).
However, this group of patients were opioid-naive, and no
comparison can be carried out with the present results. A ratio
of about 1:20 was used in this study (a dose of 200mg of OTFC
fentanyl corresponded to 4mg of IV-MO) after a preliminary
testing, also considering that in previous studies the starting dose
of OTFC for patients receiving equivalent doses of oral morphine
was 200mg (Christie et al, 1998; Farrar et al, 1998; Portenoy et al,
1999b; Coluzzi et al, 2001). As with IV-MO, OTFC doses should not
exceed 20% of patients’ around-the-clock medication, which
should be at least 60mg of oral morphine equivalents. For several
reasons, it is unlikely that an equivalency approach is feasible
under the circumstances of this study. While the availability of
IV-MO is total and then predictable, individual differences in
OTFC availability are likely, generally reduced in some patients,
who may not use correctly the stick or may have mucosal damage,
limiting absorption, although this process was monitored by
nurses by direct vision. Thus, while underdosing may occur in
some patients, producing a more limited effect than expected,
higher availability and then more absorption and overdosing with
OTFC are unlikely. This may confirm the safety of the approach
used, avoiding to start titration with minimal doses of OTFC
patients who are receiving high doses of opioids regularly. This
practice may discourage patients, particularly outpatients, to
continue titration in daily practice.
It is likely that the use of a different ratio, for example 1:10,
would have affected (improved) the efficacy of OTFC compared to
IV-MO. This means that OTFC doses of 400mg should be started in
Intravenous morphine and OTFC doses
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spatients receiving oral morphine equivalents of 60mgday
 1.
However, according to this protocol, 1600 or 3200mg should be
administered in patients receiving 240 or 480mgday
 1 of oral
morphine equivalents, respectively. Given the exploratory
nature of this study, a more prudent ratio was used. Of interest,
intensity of adverse effects were mild and acceptable in most cases,
with a rate that was similar to that reported in an open long-term
study where OTFC doses were titrated previously (Hanks et al,
2004).
Owing to lack of blindness of the study, the results should be
interpreted carefully. No placebo control was considered for such
patients requiring immediate pain relief and having available
effective medication, and who were considered not amenable
ethically with placebo, also given the exploratory use of OTFC at
doses equivalent to the basal opioid regimen, never tested in
previous OTFC studies where no correlations were found. The
double-dummy technique requiring simultaneous treatments was
unfeasible in this clinical context. The low number of patients is of
concern, and probably owing to dropout rate. However, the strict
selection criteria adopted (number and intensity of episodes,
excluding pain on movement, type of opioid used for basal
analgesia, no previous selection for adverse effects during a
titration phase) should limit this bias. In any case, the meaning of
this study should be interpreted as a preliminary experience for
evaluating the feasibility of such an approach, rather than
proposing a standard treatment, particularly given the peculiarity
of the setting where the study was performed. To collect such acute
data in real time, it was preferred to use very simple tools and
specific time intervals, avoiding other instruments, such as pain
relief intensity, which would have confused the monitoring,
introducing a further burden for patients. Fifteen minutes was
considered an acceptable interval to evaluate the treatment of pain
flares. Another possible concern is about the use of different
opioids as basal medication, which were compared in an
equianalgesic range. In previous studies and a subsequent
experience, this problem did not arise specific problems in
response to OTFC or IV-MO (Mercadante et al, 2004; Farrar
et al, 1998; Portenoy et al, 1999b; Coluzzi et al, 2001).
In conclusion, IV-MO and OTFC were equally effective for
treating breakthrough pain episodes, the effect of IV-MO being
faster. As IV-MO, OTFC used at a dose proportional to the basal
opioid regimen was safe and effective in the majority of patients
experiencing pain exacerbation, confirming figures reported
previously, but contradicting previous OTFC studies. Adverse
effects were compatible and not troublesome. Should data
regarding the risks confirmed in a larger number of patients, this
treatment could be feasible even for outpatients or home patients,
without requiring complex titration procedures.
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